| Literature DB >> 25710121 |
L Cao-Lei1, G Elgbeili2, R Massart3, D P Laplante2, M Szyf4, S King1.
Abstract
Prenatal maternal stress (PNMS) can impact a variety of outcomes in the offspring throughout childhood and persisting into adulthood as shown in human and animal studies. Many of the effects of PNMS on offspring outcomes likely reflect the effects of epigenetic changes, such as DNA methylation, to the fetal genome. However, no animal or human research can determine the extent to which the effects of PNMS on DNA methylation in human offspring is the result of the objective severity of the stressor to the pregnant mother, or her negative appraisal of the stressor or her resulting degree of negative stress. We examined the genome-wide DNA methylation profile in T cells from 34 adolescents whose mothers had rated the 1998 Québec ice storm's consequences as positive or negative (that is, cognitive appraisal). The methylation levels of 2872 CGs differed significantly between adolescents in the positive and negative maternal cognitive appraisal groups. These CGs are affiliated with 1564 different genes and with 408 different biological pathways, which are prominently featured in immune function. Importantly, there was a significant overlap in the differentially methylated CGs or genes and biological pathways that are associated with cognitive appraisal and those associated with objective PNMS as we reported previously. Our study suggests that pregnant women's cognitive appraisals of an independent stressor may have widespread effects on DNA methylation across the entire genome of their unborn children, detectable during adolescence. Therefore, cognitive appraisals could be an important predictor variable to explore in PNMS research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25710121 PMCID: PMC4445750 DOI: 10.1038/tp.2015.13
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Figure 1Differentially methylated CGs responding to cognitive appraisal level. Heatmap showing methylation of the 500 most differentially methylated CGs (P<0.003, FDR <0.055) across all 34 individuals. Each column represents an individual and each row a single CG. A color gradient intensity scale at the lower right-hand corner of the Heatmap expresses methylation changes. The darkest green indicates the lowest methylation level and the darkest red indicates the highest methylation level. The color bar above the Heatmap indicates subjects categorized by their mother's cognitive appraisal: blue indicates negative cognitive appraisal level, red indicates positive cognitive appraisal level. FDR, false discovery rate.
Top 50 most significantly differentially methylated CGs sorted by P-value and FDR
| P | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | cg19851816 | 1.18004E−06 | 0.014848438 | 22 | TUBGCP6 | Body | Island | Gene_Associated_Cell_type_specific |
| 2 | cg17901382 | 1.65517E−05 | 0.054104691 | 17 | TSEN54 | Body | S_Shore | Unclassified |
| 3 | cg17477806 | 1.95976E−05 | 0.054104691 | 19 | SEMA6B | Body | Island | |
| 4 | cg00815832 | 2.11272E−05 | 0.054104691 | 1 | Island | |||
| 5 | cg03549146 | 3.38685E−05 | 0.054104691 | 16 | MIR140;WWP2 | TSS200;Body;Body | ||
| 6 | cg27400313 | 4.05176E−05 | 0.054104691 | 18 | MBP | 5'UTR;5'UTR | Island | |
| 7 | cg15401418 | 4.79229E−05 | 0.054104691 | 17 | SEPT9 | 5'UTR;5'UTR;Body;1stExon | Promoter_Associated | |
| 8 | cg25945642 | 6.77093E−05 | 0.054104691 | 3 | SLC9A9 | Body | ||
| 9 | cg19235893 | 7.8799E−05 | 0.054104691 | 2 | S_Shelf | |||
| 10 | cg11586857 | 8.50692E−05 | 0.054104691 | 6 | LTA | 1stExon;5'UTR;5'UTR | Promoter_Associated | |
| 11 | cg03020863 | 9.10217E−05 | 0.054104691 | 11 | PDGFD | Body;Body | ||
| 12 | cg10365563 | 0.000101568 | 0.054104691 | 7 | SP4 | Body | S_Shore | |
| 13 | cg09736959 | 0.000107516 | 0.054104691 | 6 | LTA | 1stExon;5'UTR;5'UTR | Promoter_Associated | |
| 14 | cg00500359 | 0.000111231 | 0.054104691 | 11 | OSBPL5 | 5'UTR;5'UTR;5'UTR | ||
| 15 | cg00158530 | 0.000126894 | 0.054104691 | 16 | MIR140;WWP2 | TSS200;Body;Body | ||
| 16 | cg24216966 | 0.000159003 | 0.054104691 | 6 | LTA | 1stExon;5'UTR;5'UTR | Promoter_Associated | |
| 17 | cg17226602 | 0.000192559 | 0.054104691 | 5 | KIF4B | 1stExon | ||
| 18 | cg10476003 | 0.000196802 | 0.054104691 | 6 | LTA | 1stExon;5'UTR;5'UTR | Promoter_Associated | |
| 19 | cg22872349 | 0.000201684 | 0.054104691 | 15 | Island | |||
| 20 | cg21203569 | 0.000203548 | 0.054104691 | 11 | NR1H3 | TSS200;TSS200;5'UTR | ||
| 21 | cg11975397 | 0.000218701 | 0.054104691 | 1 | ||||
| 22 | cg09452568 | 0.000219239 | 0.054104691 | 5 | ESM1 | Body;Body | ||
| 23 | cg19809575 | 0.00022118 | 0.054104691 | 16 | BANP | Body;Body | Island | |
| 24 | cg01937809 | 0.000229471 | 0.054104691 | 1 | ZC3H12A | Body | S_Shore | Promoter_Associated |
| 25 | cg14597739 | 0.000234966 | 0.054104691 | 6 | LTA | TSS200;1stExon;5'UTR | Promoter_Associated | |
| 26 | cg18446110 | 0.000235149 | 0.054104691 | 5 | SLC23A1 | Body;Body | S_Shore | |
| 27 | cg07197230 | 0.000252202 | 0.054104691 | 22 | CECR2 | 1stExon | ||
| 28 | cg04057219 | 0.000253947 | 0.054104691 | 16 | ABCC1 | Body;Body;Body;Body;Body | Unclassified | |
| 29 | cg21999229 | 0.000254014 | 0.054104691 | 6 | LTA | TSS200;1stExon;5'UTR | Promoter_Associated | |
| 30 | cg05413628 | 0.000257521 | 0.054104691 | 16 | CLCN7 | Body;Body | N_Shelf | |
| 31 | cg15719903 | 0.000266739 | 0.054104691 | 12 | TAPBPL | Body | ||
| 32 | cg27136994 | 0.000288238 | 0.054104691 | 15 | C15orf26 | TSS200 | Island | Unclassified_Cell_type_specific |
| 33 | cg12810837 | 0.000291021 | 0.054104691 | 12 | CLEC2D | TSS200;TSS200 | Unclassified | |
| 34 | cg26412374 | 0.000291637 | 0.054104691 | 11 | ATL3 | Body | N_Shore | Promoter_Associated |
| 35 | cg20184271 | 0.000301168 | 0.054104691 | 12 | ||||
| 36 | cg13549277 | 0.000304238 | 0.054104691 | 12 | IFFO1 | Body;TSS1500;Body | S_Shore | |
| 37 | cg16219283 | 0.000304864 | 0.054104691 | 6 | LTA | TSS200;1stExon;5'UTR | Promoter_Associated | |
| 38 | cg04339360 | 0.000309036 | 0.054104691 | 13 | KLF5 | Body | S_Shore | Unclassified_Cell_type_specific |
| 39 | cg05350315 | 0.000311807 | 0.054104691 | 1 | LCK | 5'UTR;1stExon | S_Shelf | Promoter_Associated |
| 40 | cg04757806 | 0.000312067 | 0.054104691 | 11 | FUT4 | 1stExon | Island | |
| 41 | cg13462957 | 0.000326466 | 0.054104691 | 7 | N_Shore | Unclassified_Cell_type_specific | ||
| 42 | cg01823958 | 0.000333899 | 0.054104691 | 1 | SLC1A7 | Body | N_Shore | |
| 43 | cg22662844 | 0.000335662 | 0.054104691 | 7 | MAD1L1 | Body;Body;Body | Island | |
| 44 | cg03391657 | 0.000345581 | 0.054104691 | 1 | LOC647121 | TSS1500 | N_Shore | Unclassified_Cell_type_specific |
| 45 | cg01554529 | 0.000346945 | 0.054104691 | 1 | FBXO6;FBXO44 | TSS1500;3'UTR;3'UTR;3'UTR;3'UTR | N_Shore | |
| 46 | cg26305174 | 0.000358436 | 0.054104691 | 7 | SLC12A9;TRIP6 | Body;TSS1500 | N_Shore | |
| 47 | cg06513247 | 0.000369945 | 0.054104691 | 17 | SEPT9 | 1stExon;Body;5'UTR;Body;Body;Body;Body | N_Shore | |
| 48 | cg11186344 | 0.000372696 | 0.054104691 | 1 | IFFO2 | Body | Promoter_Associated | |
| 49 | cg03022510 | 0.000375216 | 0.054104691 | 2 | Unclassified_Cell_type_specific | |||
| 50 | cg04261496 | 0.000381463 | 0.054104691 | 7 | FOXK1 | Body | Unclassified_Cell_type_specific |
Abbreviations: FDR, false discovery rate; TSS, transcription start site; UTR, untranslated region.
Figure 2Venn diagram showing overlapping between cognitive appraisal-related and objective PNMS-related genes. (a) Top six functions of the 2872 differentially methylated genes. The y axis shows functions while the x axis shows −log(P-value). The yellow line indicates the threshold value of P<0.05. (b) For the overlap search all genes with significant change were used from cognitive appraisal versus objective PNMS data set (957 genes). The central region corresponds to genes with changed DNA methylation in both data sets. (c) For the overlap search, all biological pathways from cognitive appraisal versus that from objective PNMS data set (345 biological pathways). The central region corresponds to common biological pathways. A Fisher's exact test was used for calculating P-values for the significance of the overlaps. PNMS, prenatal maternal stress.
Seventy-five pathways which were uniquely associated with maternal cognitive appraisal of the ice storm
| − | ||
|---|---|---|
| STAT3 pathway | 3.14E+00 | SOCS1,MAP3K11,FLT1,RAC1,STAT3,JAK2,DDR1,TGFBR2,MAPK14,BMPR1A,CDKN1A,MAPK10,IGF1R,MAP2K1 |
| γ-Linolenate biosynthesis II (Animals) | 2.21E+00 | ACSL3,ACSBG1,ACSL6,CYB5R3,SLC27A1 |
| PDGF signaling | 2.01E+00 | SYNJ2,PIK3R6,PIK3R5,PLCG1,PIK3CD,STAT3,PIK3R2,JAK2,PDGFD,STAT1,MAP2K1,INPP5D |
| Agrin interactions at neuromuscular junction | 2.00E+00 | ITGB1,ITGB2,PXN,NRG2,ACTA2,MAPK10,RAC1,ITGA6,ERBB3,ITGAL,CTTN |
| DNA methylation and transcriptional repression signaling | 1.89E+00 | DNMT3B,CHD3,HDAC1,MTA2,ARID4B |
| Wnt/β-catenin signaling | 1.60E+00 | LRP5,PPARD,CSNK1G3,HDAC1,TLE1,WNT6,PPP2R5A,TGFBR2,PPP2R4,GNAO1,PPP2R2B,RARB,TLE4,CD44,PPP2R5C,LEF1,PPP2R5E,TCF7L2,WNT5A,SOX5 |
| Role of JAK1, JAK2 and TYK2 in interferon signaling | 1.56E+00 | SOCS1,IFNGR2,STAT3,JAK2,STAT1 |
| Biotin-carboxyl carrier protein assembly | 1.54E+00 | HLCS,ACACA |
| Stearate biosynthesis I (Animals) | 1.40E+00 | ACSL3,ACSBG1,PPT1,ACSL6,SLC27A1,ACOT7 |
| Renal cell carcinoma signaling | 1.17E+00 | ETS1,SLC2A1,PIK3R6,RAC1,PIK3R5,PIK3CD,HIF1A,PIK3R2,MAP2K1 |
| Semaphorin signaling in neurons | 1.08E+00 | ITGB1,FYN,CRMP1,RAC1,LIMK2,RHOH,FNBP1 |
| Tumoricidal function of hepatic natural killer cells | 1.03E+00 | PRF1,ITGAL,CASP7,FASLG |
| Oxidative ethanol degradation III | 9.70E−01 | ALDH4A1,ACSL3,ALDH1A2 |
| Remodeling of epithelial adherens junctions | 9.12E−01 | ACTR3,RAB5C,ACTA2,ZYX,TUBB4A,TUBB,IQGAP1,ARPC4 |
| Leucine degradation I | 8.64E−01 | BCAT1,HMGCL |
| Ethanol degradation IV | 8.53E−01 | ALDH4A1,ACSL3,ALDH1A2 |
| Spliceosomal cycle | 8.51E−01 | U2AF1 |
| Proline degradation | 8.51E−01 | ALDH4A1 |
| 4-Hydroxyproline degradation I | 8.51E−01 | ALDH4A1 |
| GDP-L-fucose biosynthesis I (from GDP- | 8.51E−01 | GMDS |
| Glutamate biosynthesis II | 8.51E−01 | GLUD1 |
| Glutamate degradation X | 8.51E−01 | GLUD1 |
| Fatty acid β-oxidation I | 7.61E−01 | ACSL3,ACSBG1,ACSL6,SLC27A1 |
| Regulation of the epithelial–mesenchymal transition pathway | 7.61E−01 | ETS1,PIK3R5,mir-155,WNT6,STAT3,HIF1A,JAK2,SMURF1,TGFBR2,PIK3R6,PIK3CD,LEF1,PIK3R2,PDGFD,MAP2K1,TCF7L2,WNT5A |
| Human embryonic stem cell pluripotency | 7.24E−01 | TGFBR2,BMPR1A,PIK3R6,TDGF1,PIK3R5,PIK3CD,LEF1,WNT6,PIK3R2,PDGFD,LEFTY2,TCF7L2,WNT5A |
| Ketogenesis | 7.21E−01 | ACAT2,HMGCL |
| Role of PI3K/AKT signaling in the pathogenesis of influenza | 7.08E−01 | NFKBIA,PIK3R6,GNAI1,PIK3R5,PIK3CD,PIK3R2,MAP2K1 |
| Role of NANOG in mammalian embryonic stem cell pluripotency | 7.08E−01 | IL6ST,BMPR1A,PIK3R6,PIK3R5,WNT6,PIK3CD,STAT3,PIK3R2,JAK2,MAP2K1,WNT5A |
| Trehalose degradation II (Trehalase) | 6.91E−01 | GCK |
| Glycerol-3-phosphate shuttle | 6.91E−01 | GPD2 |
| Maturity onset diabetes of young (MODY) signaling | 6.29E−01 | CACNA1D,GCK,CACNA1C |
| Choline biosynthesis III | 6.10E−01 | PLD3,PCYT1A |
| Histamine degradation | 6.10E−01 | ALDH4A1,ALDH1A2 |
| Arginine degradation I (Arginase Pathway) | 5.82E−01 | ALDH4A1 |
| Lactose degradation III | 5.82E−01 | GLB1 |
| Androgen biosynthesis | 5.63E−01 | SRD5A2,HSD17B14 |
| Urate biosynthesis/Inosine 5'-phosphate degradation | 5.63E−01 | IMPDH1,NT5C2 |
| Colanic acid building blocks biosynthesis | 5.63E−01 | GMDS,MPI |
| Isoleucine degradation I | 5.21E−01 | BCAT1,ACAT2 |
| CDP-diacylglycerol biosynthesis I | 5.21E−01 | ABHD5,LCLAT1 |
| Leukotriene biosynthesis | 5.21E−01 | DPEP1,LTC4S |
| Mevalonate pathway I | 5.21E−01 | ACAT2,HMGCR |
| tRNA charging | 5.21E−01 | FARS2,CARS2,LARS2,AARS |
| Pentose phosphate pathway (Oxidative Branch) | 5.00E−01 | H6PD |
| Glycerol degradation I | 5.00E−01 | GPD2 |
| Acetate conversion to acetyl-CoA | 5.00E−01 | ACSL3 |
| Phosphatidylglycerol biosynthesis II (Non-plastidic) | 4.48E−01 | ABHD5,LCLAT1 |
| Arginine biosynthesis IV | 4.36E−01 | GLUD1 |
| Acetyl-CoA biosynthesis I (Pyruvate Dehydrogenase Complex) | 4.36E−01 | PDHA2 |
| Superoxide radicals degradation | 4.36E−01 | SOD3 |
| Glycogen biosynthesis II (from UDP-D-Glucose) | 4.36E−01 | GBE1 |
| Chondroitin sulfate biosynthesis | 4.25E−01 | CHST2,SULT1C4,XYLT1,CHSY1,CSGALNACT1 |
| Tryptophan degradation X (Mammalian, via Tryptamine) | 4.16E−01 | ALDH4A1,ALDH1A2 |
| Endoplasmic reticulum stress pathway | 4.16E−01 | CASP7,TAOK3 |
| Dermatan sulfate biosynthesis | 3.92E−01 | CHST2,SULT1C4,XYLT1,CHSY1,CSGALNACT1 |
| Superpathway of geranylgeranyldiphosphate biosynthesis I (via Mevalonate) | 3.87E−01 | ACAT2,HMGCR |
| Phosphatidylcholine biosynthesis I | 3.85E−01 | PCYT1A |
| Thyroid hormone metabolism II (via Conjugation and/or Degradation) | 3.78E−01 | DIO1,CSGALNACT1,UGT3A1 |
| Cardiomyocyte differentiation via BMP receptors | 3.61E−01 | NPPB,BMPR1A |
| Purine nucleotides degradation II (Aerobic) | 3.61E−01 | IMPDH1,NT5C2 |
| Chondroitin sulfate biosynthesis (Late Stages) | 3.59E−01 | CHST2,SULT1C4,CHSY1,CSGALNACT1 |
| Ethanol degradation II | 3.58E−01 | ALDH4A1,ACSL3,ALDH1A2 |
| Glycoaminoglycan-protein linkage region biosynthesis | 3.41E−01 | XYLT1 |
| Polyamine regulation in colon cancer | 3.14E−01 | AZIN1,SAT2 |
| Phosphatidylethanolamine biosynthesis II | 3.05E−01 | ETNK1 |
| Calcium transport I | 2.74E−01 | ATP2B2 |
| Ketolysis | 2.74E−01 | ACAT2 |
| UDP-N-acetyl-D-galactosamine biosynthesis II | 2.74E−01 | GCK |
| Folate transformations I | 2.74E−01 | MTHFD1L |
| Dopamine degradation | 2.73E−01 | ALDH4A1,ALDH1A2 |
| Pentose phosphate pathway | 2.47E−01 | H6PD |
| Triacylglycerol degradation | 2.39E−01 | ABHD5,PNPLA2 |
| Glutaryl-CoA degradation | 2.23E−01 | ACAT2 |
| Purine nucleotides | 2.23E−01 | IMPDH1 |
| Guanosine nucleotides degradation III | 2.02E−01 | NT5C2 |
Abbreviation: STAT3, signal transducers and activators of transcription 3.